U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H11Cl2N2O2P.C4H11NO3
Molecular Weight 342.157
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PALIFOSFAMIDE TROMETHAMINE

SMILES

NC(CO)(CO)CO.OP(=O)(NCCCl)NCCCl

InChI

InChIKey=PGLRCMRTUIMSFQ-UHFFFAOYSA-N
InChI=1S/C4H11Cl2N2O2P.C4H11NO3/c5-1-3-7-11(9,10)8-4-2-6;5-4(1-6,2-7)3-8/h1-4H2,(H3,7,8,9,10);6-8H,1-3,5H2

HIDE SMILES / InChI

Molecular Formula C4H11NO3
Molecular Weight 121.135
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H11Cl2N2O2P
Molecular Weight 221.022
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Palifosfamide or ZIO-201 (isophosphoramide mustard; IPM), a bi-functional DNA alkylator, is the active metabolite of ifosfamide (IFOS). IFOS and the related drug cyclophosphamide (CPA) are widely used anti-cancer drugs. Both are pro-drugs and need to be metabolized to be active. Their clinical use is limited by the toxicity associated with some of their metabolites. Palifosfamide has shown efficacy in diverse cancer models. ZIOPHARM Oncology Inc, under license from Dekk-Tec Inc, was developing palifosfamide, a formulation of isophosphoramide mustard with tris(hydroxymethyl)aminomethane salt-stabilization (palifosfamide-tris) and previously with lysine-stabilization (palifosfamide-lys). Preclinical studies and phase I and I/II clinical trials demonstrated that palifosfamide-tris had an antitumor efficiency comparable or superior to that of ifosfamide. To date ZIO-201 is not present in ZIOPHARM pipeline.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Phosphate prodrugs of isophosphoramide mustard.
2003 Mar-Apr
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
2009 Sep
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
2010 Jan
Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
2012 Feb
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
2016 Nov 10
Patents

Sample Use Guides

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. Patients were randomly assigned 1:1 to receive doxorubicin 75 mg/m2 intravenously day 1 plus palifosfamide 150 mg/m2/d intravenously days 1 to 3 or doxorubicin plus placebo once every 21 days for up to six cycles. The primary end point was progression-free survival (PFS) by independent radiologic review.
Route of Administration: Intravenous
Palifosfamide lysine was cytotoxic against all the osteosarcome cell lines tested with the IC(50) ranging from 0.5 to 1.5 microg/ml except for OS222, which had an IC(50) of 7 microg/ml.
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:41:08 UTC 2023
Edited
by admin
on Sat Dec 16 01:41:08 UTC 2023
Record UNII
0X5A3C04ID
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PALIFOSFAMIDE TROMETHAMINE
USAN   WHO-DD  
USAN  
Official Name English
PHOSPHORODIAMIDIC ACID, N,N'-BIS(2-CHLOROETHYL)-, COMPD. WITH 2-AMINO-2-(HYDROXYMETHYL)-1,3-PROPANEDIOL (1:1)
Common Name English
Palifosfamide tromethamine [WHO-DD]
Common Name English
PALIFOSFAMIDE TROMETHAMINE [USAN]
Common Name English
PALIFOSFAMIDE-TRIS
Common Name English
ZIO-201-T
Code English
Classification Tree Code System Code
NCI_THESAURUS C697
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C95703
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
SMS_ID
100000137631
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
FDA UNII
0X5A3C04ID
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
EPA CompTox
DTXSID00147888
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
PUBCHEM
46926367
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
EVMPD
SUB76137
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
USAN
AB-06
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
ChEMBL
CHEMBL889
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
CAS
1070409-31-2
Created by admin on Sat Dec 16 01:41:08 UTC 2023 , Edited by admin on Sat Dec 16 01:41:08 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY